A Randomized,Controlled,Open-label,Prospective,Single-center Study to Investigate the Neoadjuvant Therapy of SHR-1210 in Combination With Carboplatin and Paclitaxel-albumin in Combination With Carboplatin and Paclitaxel in Resectable NSCLC

Xuanwu Hospital, Beijing0 sites38 target enrollmentOctober 8, 2019

ConditionsLung Cancer Stage II PD-1 Antibody Non-small Cell Lung Cancer

InterventionsSHR-1210 Carboplatin and Paclitaxel-albumin

DrugsSHR-1210 Carboplatin and Paclitaxel-albumin

Overview

Phase: Phase 2
Intervention: SHR-1210
Conditions: Lung Cancer Stage II
Sponsor: Xuanwu Hospital, Beijing
Enrollment: 38
Primary Endpoint: Major pathologic response
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to evaluate the major pathologic response of SHR-1210 + carboplatin + paclitaxel-albumin in subjects with resectable non-small cell lung cancer. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

Detailed Description

In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Subjects who randomized into control will have the opportunity to receive the treatment of carboplatin + paclitaxel-albumin therapy after confirmed disease progression. Treatment cycles of chemotherapy will be 2.

Registry

clinicaltrials.gov

Start Date

October 8, 2019

End Date

July 31, 2021

Last Updated

6 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Xuanwu Hospital, Beijing

Responsible Party

Principal Investigator

zhangyi

Chief physician

Xuanwu Hospital, Beijing

Eligibility Criteria

Inclusion Criteria

•Male or female 18-70 years of age.
•ECOG performance status of 0 or
•Life expectancy ≥ 12 weeks.
•Subjects are diagnosed with histologically or cytologically confirmed NSCLC.
•Subjects are diagnosed with resectable stage II, stage IIIA non-small cell lung cancer.
•Subjects enrolled must have measurable lesion(s) according to the RECIST 1.1 standard (the CT scan length of the tumor lesion \> 10 mm, the short diameter of CT scan of the lymph node lesions \> 15 mm).
•Subjects haven't received radiotherapy, chemotherapy, surgery and targeted therapy before admission.
•Subjects must have adequate pulmonary function for expected pneumonectomy.
•The main organ's function is normal and it should meet the following criteria:
•(1)Blood routine examination should be complied with (No blood transfusion, no use of hematopoietic factors and no use of drugs for correction within 14 days):

Exclusion Criteria

•Subjects have symptomatic central nervous system metastasis.
•Subjects have a history of any active autoimmune disease or autoimmune disease including but not limited to the following: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism which can be included after hormone replacement therapy; Subjects with childhood asthma have been completely alleviated and without any intervention or vitiligo in adulthood can be included. Subjects who need medical intervention with bronchodilators can not be included.
•Subjects with congenital or acquired immunodeficiency such as HIV infection, active hepatitis B (HBV DNA ≥ 500 IU/ml), hepatitis C (hepatitis C antibody is positive and HCV-RNA is higher than the lower detection limit of the analysis method) or co-infection with hepatitis B and hepatitis C.
•Subjects used immunosuppressive drugs excluding nasal spray and inhaled corticosteroids or systemic steroids at physiological doses(prednisolone≤10 mg/day or other corticosteroids of the same pharmacophysiological dose) within 14 days before the first dose.
•Subjects were vaccinated with live attenuated vaccine within 4 weeks before the first dose or during the study period.
•Subjects has taken last systemic cytotoxic or radiotherapy treatment in the past 4 weeks or subjects are currently using other antineoplastic drugs.
•Subjects suffered from other malignant tumors in the past three years.
•There is evidence that subjects have pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-induced pneumonia and severe impairment of lung function.
•Subjects have uncontrollable hypertension (systolic pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg), despite patients have taken the best drug treatment;
•Subjects with grade II or above myocardial ischemia or myocardial infarction and poorly controlled arrhythmias (QTc interval \> 450 ms for males and QTc interval \< 470 ms for females). Subjects with grade III-IV cardiac insufficiency or with left ventricular ejection fraction (LVEF) less than 50% had myocardial infarction within 6 months before admission according to NYHA criteria. Subjects with grade II or above heart failure, uncontrolled angina, uncontrolled severe ventricular arrhythmias, clinically pericardial disease, acute ischemia or abnormal active conduction system.

Arms & Interventions

SHR-1210+Carboplatin+Paclitaxel-albumin

Subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.

Intervention: SHR-1210